制药公司AstraZeneca原定于2026年11月1日停止向澳大利亚药品福利计划(PBS)供应月度Zoladex植入剂(3.6mg)，这一决定引发了乳腺癌和子宫内膜异位症患者的广泛担忧。1患者Ashleigh Middleton通过请愿书动员了公众力量，该请愿书获得超过42000人的签署。1面对舆论压力，AstraZeneca于2026年7月16日宣布逆转决定。1
根据新政策，符合条件且没有合适替代治疗方案的患者可通过Zoladex持续项目免费无限期获得该药物。1AstraZeneca发言人强调，"Zoladex持续项目不是有时间限制的项目"。1医学专家指出，月度高剂量(3.6mg)植入剂在激素抑制方面优于三个月一次的高剂量制剂(10.8mg)，对年轻女性尤其如此。1澳大利亚是全球唯一受原停供决定影响的市场。1截至2025年，共有13580名患者在使用该药物。1详细的患者注册和入群信息将于9月发布。1
Pharmaceutical company AstraZeneca has reversed its plan to discontinue supplying monthly Zoladex injections (3.6mg) to Australia's Pharmaceutical Benefits Scheme (PBS) starting November 2026.1 On July 16, 2026, the company announced it would instead provide the medication free of charge indefinitely to patients without suitable alternative treatments.1
The reversal came after patient advocacy efforts gained significant traction. Ashleigh Middleton initiated a Change.org petition against the withdrawal, which garnered more than 42,000 signatures.1 As of 2025, approximately 13,580 Australian patients were using the drug.1 An AstraZeneca spokesperson confirmed the new arrangement, stating that "the Zoladex Continuity Program is not a time-limited program."1
Medical experts have noted that the monthly high-dose formulation (3.6mg) provides superior hormone suppression for younger women compared to the quarterly high-dose option (10.8mg).1 Australia is the only global market affected by the original discontinuation decision.1 Detailed enrollment procedures and program information are scheduled for release in September.1
评论
还没有评论，欢迎留下第一条。